Pharsight

1. Macrilen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6861409	NOVO	Growth hormone secretagogues	Aug, 2022 (1 year, 2 months ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719	NOVO	Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds	Oct, 2027 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 20, 2024

Drugs and Companies using MACIMORELIN ACETATE ingredient

Market Authorisation Date: 20 December, 2017

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
EQ 60MG BASE/POUCH	FOR SOLUTION;ORAL	Prescription

MACRILEN family patents

2. Ozempic patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP06725149A	2011-05-04	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected
EP04797453A	2018-08-20	Sandoz AG	Opposition rejected
EP04797453A	2018-08-20	Fresenius Kabi Deutschland GmbH	Opposition rejected
EP04797453A	2018-08-21	Wittkopp, Alexander	Opposition rejected
EP04797453A	2018-08-21	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP04797453A	2018-08-21	Generics (U.K.) Limited	Opposition rejected
EP04797453A	2018-08-22	Uexküll & Stolberg Partnerschaft von Patent- und Rechtsanwälten mbB	Opposition rejected
EP17196501A	2019-12-04	Galenicum Health S.L.U.	Granted and Under Opposition
EP17196501A	2019-12-04	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP17196501A	2019-12-05	Dr. Reddy's Laboratories Limited	Granted and Under Opposition
EP17196501A	2019-12-06	Hoffmann Eitle	Granted and Under Opposition
EP17196501A	2019-12-06	Generics (U.K.) Limited	Granted and Under Opposition
EP06762643A	2010-07-30	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP05796880A	2010-07-12	Genentech, Inc.	Granted and Under Opposition
EP05796880A	2010-07-12	COPERNICUS sp. zo.o.	Granted and Under Opposition
EP05796880A	2010-07-13	Ferring International Center S.A.	Granted and Under Opposition
EP05796880A	2010-07-13	OWEN MUMFORD LIMITED	Granted and Under Opposition
EP05796880A	2010-07-14	Ypsomed AG	Granted and Under Opposition
EP05796880A	2010-07-14	Stöckeler, Ferdinand	Granted and Under Opposition
EP02726984A	2006-02-23	OWEN MUMFORD LIMITED	Patent maintained as amended
EP02726984A		Genentech, Inc.	Patent maintained as amended
EP02726984A	2006-03-01	TecPharma Licensing AG	Patent maintained as amended
EP06121820A	2010-05-18	SANOFI-AVENTIS DEUTSCHLAND GMBH	Opposition rejected
EP13737808A	2021-01-07	Teva Pharmaceutical Industries LTD.	Granted and Under Opposition
EP13737808A	2021-01-07	Generics [UK] Limited	Granted and Under Opposition
EP13737808A	2021-01-08	Galenicum Health S.L.U.	Granted and Under Opposition
EP06701034A	2018-01-19	Schwöbel, Thilo	Opposition rejected
EP06754730A	2011-11-30	WMC Matthes Consulting	Patent maintained as amended
EP06754730A	2011-12-02	Ypsomed AG	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8536122	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US10335462	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US8129343	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US8114833	March, 2022	Terminated-Settled	Novo Nordisk A/S	Fresenius Kabi USA, LLC
US8114833	July, 2020	Terminated-Settled	Novo Nordisk A/S	Pfizer Inc.
US8114833	December, 2019	Terminated-Settled	Novo Nordisk A/S et al.	Pfizer Inc. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122	NOVO	Acylated GLP-1 compounds	Mar, 2026 (2 years from now)
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (8 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699	NOVO	Automatic injection device with reset feature	Jan, 2022 (1 year, 8 months ago)
US8672898	NOVO	Automatic injection device with reset feature	Jan, 2022 (1 year, 8 months ago)
US9486588	NOVO	Automatic injection device with reset feature	Jan, 2022 (1 year, 8 months ago)
US8579869	NOVO	Needle mounting system and a method for mounting a needle assembly	Jun, 2023 (3 months ago)
US7762994	NOVO	Needle mounting system and a method for mounting a needle assembly	May, 2024 (7 months from now)
US8114833	NOVO	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices	Aug, 2025 (1 year, 10 months from now)
US11446443	NOVO	Injection device with torsion spring and rotatable display	Oct, 2025 (2 years from now)
US8684969	NOVO	Injection device with torsion spring and rotatable display	Oct, 2025 (2 years from now)
US9861757	NOVO	Injection device with an end of dose feedback mechanism	Jan, 2026 (2 years from now)
US10357616	NOVO	Injection device with an end of dose feedback mechanism	Jan, 2026 (2 years from now)
US9616180	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (2 years from now)
US9108002	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (2 years from now)
US10376652	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (2 years from now)
US11311679	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (2 years from now)
US11097063	NOVO	Syringe device with a dose limiting mechanism and an additional safety mechanism	Jul, 2026 (2 years from now)
US10220155	NOVO	Syringe device with a dose limiting mechanism and an additional safety mechanism	Jul, 2026 (2 years from now)
US8920383	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jul, 2026 (2 years from now)
US9775953	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jul, 2026 (2 years from now)
USRE46363	NOVO	Dial-down mechanism for wind-up pen	Aug, 2026 (2 years from now)
US9687611	NOVO	Injection device with torsion spring and rotatable display	Feb, 2027 (3 years from now)
US9457154	NOVO	Injection device with an end of dose feedback mechanism	Sep, 2027 (3 years from now)
US9132239	NOVO	Dial-down mechanism for wind-up pen	Feb, 2032 (8 years from now)
US10335462	NOVO	Use of long-acting GLP-1 peptides	Jun, 2033 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication (I)	Jan 16, 2023
New Dosing Schedule (D)	Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to imp...

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg/1.5 mL and 4 mg/3 mL	06 Dec, 2021	7		21 Jun, 2033
8 mg/3 mL	21 Dec, 2022	1		01 Feb, 2032

Strength	Dosage	Availability
2MG/1.5ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription
4MG/3ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

OZEMPIC family patents

3. Rybelsus patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17204363A	2020-12-04	Galenicum Health S.L.U.	Granted and Under Opposition
EP17204363A	2020-12-04	Generics (U.K.) Limited	Granted and Under Opposition
EP17204363A	2020-12-03	Hexal AG	Granted and Under Opposition
EP17204363A	2020-12-01	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP14721834A	2019-05-15	Sanofi	Granted and Under Opposition
EP14721834A	2019-05-15	Hexal AG	Granted and Under Opposition
EP14721834A	2019-05-15	Galenicum Health S.L.U.	Granted and Under Opposition
EP14721834A	2019-05-15	Lederer & Keller Patentanwälte Partnerschaft mbB	Granted and Under Opposition
EP14721834A	2019-05-15	Generics (U.K.) Limited	Granted and Under Opposition
EP13709231A	2019-05-15	Galenicum Health S.L.U.	Granted and Under Opposition
EP13709231A	2019-05-15	Hexal AG	Granted and Under Opposition
EP13709231A	2019-05-15	Generics (U.K.) Limited	Granted and Under Opposition
EP14721834A	2019-05-13	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP13709231A	2019-05-13	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP11805824A	2018-09-13	Generics (U.K.) Limited	Granted and Under Opposition
EP11805824A	2018-09-13	Hexal AG	Granted and Under Opposition
EP11805824A	2018-09-13	Galenicum Health S.L.	Granted and Under Opposition
EP11805824A	2018-09-12	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP06725149A	2011-05-04	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8129343	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US8536122	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122	NOVO	Acylated GLP-1 compounds	Mar, 2026 (2 years from now)
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (8 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10960052	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid	Dec, 2031 (8 years from now)
US9278123	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid	Dec, 2031 (8 years from now)
US10086047	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid	Dec, 2031 (8 years from now)
US11382957	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid	Dec, 2031 (8 years from now)
US10933120	NOVO	Compositions of GLP-1 peptides and preparation thereof	Mar, 2033 (9 years from now)
US10278923	NOVO	Oral dosing of GLP-1 compounds	May, 2034 (10 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M (M)	Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 20 September, 2019

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription
7MG	TABLET;ORAL	Prescription
14MG	TABLET;ORAL	Prescription

RYBELSUS family patents

4. Saxenda patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP04797453A	2018-08-20	Sandoz AG	Opposition rejected
EP04797453A	2018-08-20	Fresenius Kabi Deutschland GmbH	Opposition rejected
EP04797453A	2018-08-21	Wittkopp, Alexander	Opposition rejected
EP04797453A	2018-08-21	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP04797453A	2018-08-21	Generics (U.K.) Limited	Opposition rejected
EP04797453A	2018-08-22	Uexküll & Stolberg Partnerschaft von Patent- und Rechtsanwälten mbB	Opposition rejected
EP02745182A	2008-09-26	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected
EP17196501A	2019-12-04	Galenicum Health S.L.U.	Granted and Under Opposition
EP17196501A	2019-12-04	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP17196501A	2019-12-05	Dr. Reddy's Laboratories Limited	Granted and Under Opposition
EP17196501A	2019-12-06	Hoffmann Eitle	Granted and Under Opposition
EP17196501A	2019-12-06	Generics (U.K.) Limited	Granted and Under Opposition
EP06762643A	2010-07-30	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP05796880A	2010-07-12	Genentech, Inc.	Granted and Under Opposition
EP05796880A	2010-07-12	COPERNICUS sp. zo.o.	Granted and Under Opposition
EP05796880A	2010-07-13	Ferring International Center S.A.	Granted and Under Opposition
EP05796880A	2010-07-13	OWEN MUMFORD LIMITED	Granted and Under Opposition
EP05796880A	2010-07-14	Ypsomed AG	Granted and Under Opposition
EP05796880A	2010-07-14	Stöckeler, Ferdinand	Granted and Under Opposition
EP02726984A	2006-02-23	OWEN MUMFORD LIMITED	Patent maintained as amended
EP02726984A		Genentech, Inc.	Patent maintained as amended
EP02726984A	2006-03-01	TecPharma Licensing AG	Patent maintained as amended
EP06121820A	2010-05-18	SANOFI-AVENTIS DEUTSCHLAND GMBH	Opposition rejected
EP17710160A	2022-04-28	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP17710160A	2022-05-03	SANDOZ AG	Granted and Under Opposition
EP17710160A	2022-05-03	Adalvo Ltd.	Granted and Under Opposition
EP17710160A	2022-05-04	STADA Arzneimittel AG	Granted and Under Opposition
EP17710160A	2022-05-04	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP06701034A	2018-01-19	Schwöbel, Thilo	Opposition rejected
EP06754730A	2011-11-30	WMC Matthes Consulting	Patent maintained as amended
EP06754730A	2011-12-02	Ypsomed AG	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8114833	March, 2022	Terminated-Settled	Novo Nordisk A/S	Fresenius Kabi USA, LLC
US8114833	July, 2020	Terminated-Settled	Novo Nordisk A/S	Pfizer Inc.
US8114833	December, 2019	Terminated-Settled	Novo Nordisk A/S et al.	Pfizer Inc. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6268343	NOVO	Derivatives of GLP-1 analogs	Aug, 2022 (1 year, 1 month ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486588	NOVO	Automatic injection device with reset feature	Jan, 2022 (1 year, 8 months ago)
US8672898	NOVO	Automatic injection device with reset feature	Jan, 2022 (1 year, 8 months ago)
US8846618	NOVO	Stable formulation of modified GLP-1	Jun, 2022 (1 year, 3 months ago)
US6899699 (Pediatric)	NOVO	Automatic injection device with reset feature	Jul, 2022 (1 year, 3 months ago)
US8672898 (Pediatric)	NOVO	Automatic injection device with reset feature	Jul, 2022 (1 year, 3 months ago)
US9486588 (Pediatric)	NOVO	Automatic injection device with reset feature	Jul, 2022 (1 year, 3 months ago)
US8846618 (Pediatric)	NOVO	Stable formulation of modified GLP-1	Dec, 2022 (9 months ago)
US6268343 (Pediatric)	NOVO	Derivatives of GLP-1 analogs	Feb, 2023 (7 months ago)
US8579869	NOVO	Needle mounting system and a method for mounting a needle assembly	Jun, 2023 (3 months ago)
US8579869 (Pediatric)	NOVO	Needle mounting system and a method for mounting a needle assembly	Dec, 2023 (2 months from now)
US7762994	NOVO	Needle mounting system and a method for mounting a needle assembly	May, 2024 (7 months from now)
US7762994 (Pediatric)	NOVO	Needle mounting system and a method for mounting a needle assembly	Nov, 2024 (1 year, 1 month from now)
US8114833	NOVO	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices	Aug, 2025 (1 year, 10 months from now)
US11446443	NOVO	Injection device with torsion spring and rotatable display	Oct, 2025 (2 years from now)
US8684969	NOVO	Injection device with torsion spring and rotatable display	Oct, 2025 (2 years from now)
US9616180	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (2 years from now)
US11311679	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (2 years from now)
US9861757	NOVO	Injection device with an end of dose feedback mechanism	Jan, 2026 (2 years from now)
US10357616	NOVO	Injection device with an end of dose feedback mechanism	Jan, 2026 (2 years from now)
US10376652	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (2 years from now)
US9108002	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (2 years from now)
US8114833 (Pediatric)	NOVO	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices	Feb, 2026 (2 years from now)
US8684969 (Pediatric)	NOVO	Injection device with torsion spring and rotatable display	Apr, 2026 (2 years from now)
US10220155	NOVO	Syringe device with a dose limiting mechanism and an additional safety mechanism	Jul, 2026 (2 years from now)
US8920383	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jul, 2026 (2 years from now)
US9775953	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jul, 2026 (2 years from now)
US11097063	NOVO	Syringe device with a dose limiting mechanism and an additional safety mechanism	Jul, 2026 (2 years from now)
US9616180 (Pediatric)	NOVO	Automatic injection device with a top release mechanism	Jul, 2026 (2 years from now)
US9861757 (Pediatric)	NOVO	Injection device with an end of dose feedback mechanism	Jul, 2026 (2 years from now)
US9108002 (Pediatric)	NOVO	Automatic injection device with a top release mechanism	Jul, 2026 (2 years from now)
USRE46363	NOVO	Dial-down mechanism for wind-up pen	Aug, 2026 (2 years from now)
US9775953 (Pediatric)	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jan, 2027 (3 years from now)
US10220155 (Pediatric)	NOVO	Syringe device with a dose limiting mechanism and an additional safety mechanism	Jan, 2027 (3 years from now)
US8920383 (Pediatric)	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jan, 2027 (3 years from now)
USRE46363 (Pediatric)	NOVO	Dial-down mechanism for wind-up pen	Feb, 2027 (3 years from now)
US9687611	NOVO	Injection device with torsion spring and rotatable display	Feb, 2027 (3 years from now)
US9687611 (Pediatric)	NOVO	Injection device with torsion spring and rotatable display	Aug, 2027 (3 years from now)
US9457154	NOVO	Injection device with an end of dose feedback mechanism	Sep, 2027 (3 years from now)
US9457154 (Pediatric)	NOVO	Injection device with an end of dose feedback mechanism	Mar, 2028 (4 years from now)
US9132239	NOVO	Dial-down mechanism for wind-up pen	Feb, 2032 (8 years from now)
US9132239 (Pediatric)	NOVO	Dial-down mechanism for wind-up pen	Aug, 2032 (8 years from now)
US9968659	NOVO	Liraglutide in cardiovascular conditions	Jan, 2037 (13 years from now)
US9968659 (Pediatric)	NOVO	Liraglutide in cardiovascular conditions	Jul, 2037 (13 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population (NPP)	Dec 4, 2023

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
18 mg/3 mL prefilled syringe	16 Aug, 2021	1		09 Jan, 2037

Strength	Dosage	Availability
18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

SAXENDA family patents

5. Wegovy patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP13737808A	2021-01-08	Galenicum Health S.L.U.	Granted and Under Opposition
EP13737808A	2021-01-07	Teva Pharmaceutical Industries LTD.	Granted and Under Opposition
EP13737808A	2021-01-07	Generics [UK] Limited	Granted and Under Opposition
EP06725149A	2011-05-04	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8129343	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US8536122	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122	NOVO	Acylated GLP-1 compounds	Mar, 2026 (2 years from now)
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (8 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003	NOVO	Use of long-acting GLP-1 peptides	Jun, 2033 (9 years from now)
US10888605	NOVO	GLP-1 compositions and uses thereof	Aug, 2038 (14 years from now)
US11318191	NOVO	GLP-1 compositions and uses thereof	Feb, 2041 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Jun 4, 2024
New Patient Population (NPP)	Dec 23, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL	20 Oct, 2022	1		17 Feb, 2041

Strength	Dosage	Availability
0.25MG/0.5ML (0.25MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
0.5MG/0.5ML (0.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
1MG/0.5ML (1MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
1.7MG/0.75ML (1.7MG/0.75ML)	SOLUTION;SUBCUTANEOUS	Prescription
2.4MG/0.75ML (2.4MG/0.75ML)	SOLUTION;SUBCUTANEOUS	Prescription